EyePoint's Duravyu: Advancing Wet AMD Treatment with Completed Phase III & Sustained Delivery Breakthroughs

EyePoint Pharmaceuticals has successfully concluded Phase III enrollment for Duravyu (EYP-1901), a groundbreaking sustained-release therapy for wet Age-related Macular Degeneration (wet AMD). With over 400 subjects across the pivotal LUCIA and LUGANO trials